Medical Licensing (MD/DO) · Independent exam preparation
ABPN Vascular Neurology Initial Certification: Clinical Reasoning Guide Study Guide
Study stroke mechanisms, localization, imaging, acute treatment, prevention, complications, and professional practice across both dimensions of the ABPN outline.
By CertMedbry · Updated 17 October 2026
Connect vascular mechanisms and examination findings to diagnostic tests, treatment choices, prevention, and recovery. These 60 selective concepts include substantive lessons from every official disorder/topic and competency/mechanism domain. They do not cover every listed condition or reproduce examination weighting. The official detailed ABPN content specifications define the full preparation scope.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification pathway does this guide cover?
This guide covers ABPN's Certification Examination in Vascular Neurology for initial subspecialty certification. Certification in neurology or neurology with special qualification in child neurology is a prerequisite credential. Continuing certification is a separate process. Current applicants generally require one year of the specified ACGME-accredited vascular neurology fellowship training; the historical practice pathway operated during 2005–2009.
What are the examination length and question format?
The linked Format and Scoring document specifies 220 stand-alone, one-best-answer multiple-choice questions in four sections of 55. Total testing time is 240 minutes: five minutes for the nondisclosure agreement and instructions, 230 minutes for questions, and five minutes for the survey. Questions can be skipped or flagged for review.
How do breaks and scoring work?
Optional breaks occur between sections and consume examination time. ABPN uses a performance standard rather than a predefined passing rate. Items included solely for research or pretesting are excluded from scoring; their number is unspecified. There is no guessing penalty, so candidates should answer every question.
Which blueprint and examination dates apply?
ABPN's current initial-certification page lists October 19–23, 2026 and links the content specifications dated December 22, 2023. That is the document date; a separate effective date is not stated.
ABPN: Vascular Neurology · ABPN Vascular Neurology Certification Content Specifications
What are all the official disorder/topic domains?
Dimension 1 assigns Vascular neurology 77–87% and Questions not associated with a specific neurologic disorder 7–11%. Each of these nine domains receives 1–2%: Headache and pain disorders; Epilepsy and episodic disorders; Sleep disorders; Neuroinfectious diseases; Brain and spinal trauma and spinal diseases; Neuro-ophthalmologic and neuro-otologic disorders; Metabolic diseases, nutritional deficiency states, and disorders due to toxins, drugs, and physical agents; Behavioral neurology and neurocognitive disorders; and Neuroimmunologic and paraneoplastic CNS disorders. All receive a dedicated concept here, but their complete topic lists require the official outline.
ABPN Vascular Neurology Certification Content Specifications
What are all the official competency/mechanism domains?
Dimension 2 assigns Neuroscience and mechanism of disease 8–12%; Clinical aspects of neurologic disease 22–28%; Diagnostic procedures 22–28%; Treatment/Management 31–39%; Interpersonal and communication skills 1–2%; Professionalism 1–2%; Practice-based learning and improvement 1–2%; and Systems-based practice 1–3%. Every official item receives one classification on each dimension. Percentages from the two dimensions must not be added together.
ABPN Vascular Neurology Certification Content Specifications
How representative are these practice questions and flashcards?
Each set contains 16 vascular items, two nonspecific methods or practice items, one headache item, and one sleep item. Their competency emphases are two mechanism, five clinical, five diagnostic, six management, one learning/improvement, and one systems-practice item. The concepts also address communication, professionalism, and the smaller disorder domains. Neither practice set reproduces every official percentage or samples every domain. Use the official detailed outline as the full preparation checklist.
ABPN Vascular Neurology Certification Content Specifications
ABPN classifies each examination item on two overlapping axes: a disorder/topic and a competency/mechanism. The domain field identifies each lesson's main teaching emphasis; question and flashcard subtopics identify the competency dimension. A lesson can address additional domains through its clinical content. These independently authored educational materials are not official ABPN examination items.
Outline used: ABPN Vascular Neurology Certification Content Specifications, dated December 22, 2023; linked from ABPN's current initial-certification page for the October 19–23, 2026 examination and verified on 2026-10-09. A separate effective date is not stated. The workbook label maps to the official Certification Examination in Vascular Neurology; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Headache and pain disorders1–2%
40.How does migraine aura evolve differently from a typical TIA?
Migraine aura consists of fully reversible neurologic symptoms with characteristic evolution. ICHD-3 features include gradual spread, successive symptoms, and individual symptoms commonly lasting 5–60 minutes. Positive visual or sensory phenomena are useful clues. Typical ischemic deficits are often abrupt and negative, but this distinction is probabilistic rather than an exclusion rule. A first, substantially changed, or otherwise concerning episode requires attention to vascular and other secondary explanations.
Apply it
A shimmering visual pattern spreads over ten minutes before migrating hand tingling appears. Explain why the progression and positive symptom quality favor aura over an abruptly maximal negative deficit.
Common pitfall: Headache does not exclude stroke, and aura can include negative symptoms. Complete recovery alone cannot distinguish migraine from TIA because both may resolve.
Epilepsy and episodic disorders1–2%
41.When should an unexplained post-hemorrhage mental-status change prompt EEG?
Seizures after ICH may be clinical or electrographic, and impaired consciousness can obscure recognition. Continuous EEG is appropriate when mental status is unexplained, abnormal, or fluctuating and seizures are suspected. Confirmed clinical or electrographic seizures warrant treatment. This diagnostic approach differs from routinely prescribing prophylactic antiseizure medication to every patient without evidence of seizures, which does not improve the outcomes targeted by the ICH guideline.
Apply it
A patient has repeated periods of reduced responsiveness without a new structural explanation. Use EEG to investigate a possible electrical cause rather than requiring visible convulsions.
Common pitfall: Investigating suspected nonconvulsive seizures does not justify universal prophylaxis. Structural, metabolic, and medication-related causes remain possible, so EEG answers one defined question within the evaluation.
AHA/ASA: 2022 Spontaneous Intracerebral Hemorrhage Clinical Update
Sleep disorders1–2%
42.Which sleep test is preferred when obstructive apnea is suspected after stroke?
Obstructive sleep apnea requires objective diagnostic testing; questionnaires alone do not establish the diagnosis. The AASM guideline recommends polysomnography rather than home sleep apnea testing for patients with a history of stroke. Snoring, witnessed apneas, and daytime sleepiness support suspicion but do not replace a diagnostic study. The testing pathway must account for the patient's clinical context rather than assuming that recommendations for uncomplicated adults apply equally after stroke.
Apply it
A stroke survivor asks whether a high questionnaire score confirms apnea. Explain the distinction between estimating risk and establishing the diagnosis, and select polysomnography.
Common pitfall: Do not dismiss fatigue as a stroke consequence when witnessed apneas suggest another disorder. An apparently uncomplicated examination does not negate the guideline's stroke-history recommendation.
AASM Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea
Vascular neurology77–87%
1.What does a perfusion mismatch reveal about threatened brain?
An ischemic core estimate represents severely injured tissue, whereas a larger region of delayed perfusion may contain threatened tissue that remains salvageable. Their mismatch supplies a physiologic rationale for reperfusion: restoring flow may preserve tissue outside the core. DEFUSE 3 demonstrated thrombectomy benefit in selected patients with proximal anterior-circulation occlusion and favorable imaging 6–16 hours after last known well. Its enrollment thresholds describe that study population rather than every contemporary treatment pathway.
Apply it
For a patient presenting nine hours after last known well with an internal carotid occlusion and substantial mismatch, connect the vascular target and tissue findings to urgent thrombectomy assessment.
Common pitfall: Delayed perfusion does not mean irreversible infarction. Conversely, favorable mismatch cannot guarantee recovery or replace assessment of disability, established injury, and procedural suitability.
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
2.How do DWI and ADC distinguish restricted diffusion from persistent brightness?
Acute ischemia commonly produces high diffusion-weighted signal with reduced apparent diffusion coefficient, reflecting restricted water movement. DWI brightness alone is insufficient because T2-related signal can also make a lesion bright. ADC evolves over time and may approach normal during the subacute period even though tissue remains injured. Interpretation combines diffusion maps, other sequences, symptom timing, and lesion distribution rather than assigning lesion age from one bright image.
Apply it
Compare two DWI-bright lesions: one with low ADC and another with near-normal ADC and established FLAIR change. Explain how their combined sequences can indicate different stages of injury.
Common pitfall: ADC pseudonormalization does not establish tissue recovery. Normal ADC accompanying DWI brightness also cannot precisely date a lesion without clinical chronology and the remaining sequences.
4.Why can a low stroke scale score still represent disabling ischemia?
A numerical stroke severity score does not fully capture a deficit's functional effect. Severe isolated aphasia, loss of useful hand function, or visual impairment may prevent essential activities despite a low total score. Acute reperfusion assessment therefore requires an explicit description of disability as well as timing, imaging, baseline function, and contraindications. The 2026 acute ischemic stroke guidance distinguishes disabling deficits from genuinely nondisabling presentations rather than allowing numerical mildness alone to determine treatment.
Apply it
A translator develops severe isolated aphasia within the early treatment window. Explain why inability to communicate constitutes disability even when the total NIHSS score is relatively low.
Common pitfall: Do not equate a low score with nondisability. Conversely, assess the actual functional consequences rather than assuming that every measurable deficit has the same treatment implications.
AHA/ASA: Top Things to Know—2026 Acute Ischemic Stroke Guideline
5.When does a nondisabling presentation favor antiplatelet treatment?
For eligible patients with nondisabling acute ischemic deficits within 4.5 hours, the 2026 guidance favors dual antiplatelet therapy over intravenous thrombolysis. The distinction requires examination of function rather than reliance on NIHSS alone. Hemorrhage must be excluded, and treatment selection still depends on mechanism, bleeding risk, contraindications, and any recent reperfusion treatment. This acute comparison does not establish that every minor stroke should receive the same antiplatelet combination or duration.
Apply it
A patient has isolated sensory loss without interference with walking, communication, or usual tasks. Confirm nondisability and hemorrhage exclusion before applying the relevant antiplatelet pathway.
Common pitfall: Severe aphasia or loss of essential hand function can be disabling despite a low score. Do not extend a defined early-window recommendation to all presentations.
AHA/ASA: Top Things to Know—2026 Acute Ischemic Stroke Guideline
6.How does unknown onset change thrombolysis and imaging selection?
The 2026 MRI-selected pathway supports intravenous thrombolysis for eligible unknown-onset ischemic stroke when treatment can begin within 4.5 hours of symptom recognition, MRI shows a DWI lesion smaller than one-third of the MCA territory, and there is no marked corresponding FLAIR signal change. Other eligibility requirements remain essential, including a disabling deficit, exclusion of hemorrhage, acceptable blood pressure, and assessment of bleeding contraindications. DWI–FLAIR mismatch estimates lesion evolution; perfusion mismatch compares estimated core with a larger hypoperfused region. These are distinct selection approaches. Arterial occlusion and thrombectomy eligibility require a separate assessment.
Apply it
A patient last well the previous evening awakens aphasic at 06:30. At 08:00, MRI shows a small DWI lesion occupying less than one-third of the MCA territory without marked corresponding FLAIR change. If other criteria are met, initiate MRI-selected thrombolysis within 4.5 hours of the 06:30 recognition time. Assess an accompanying M1 occlusion separately for thrombectomy without delaying transfer.
Common pitfall: Recognition time supplies the clock for this defined MRI-selected pathway; it does not establish witnessed onset or replace last known well in other pathways. DWI brightness alone, any amount of FLAIR mismatch, or a proximal occlusion alone does not establish thrombolysis eligibility.
prabhakaran-et-al-2026-2026-guideline-for-the-early-management-of-patients-with-acute-ischemic-stroke-a-guideline-from_%281%29_2.pdf · Evolution of Apparent Diffusion Coefficient, Diffusion-Weighted, and T2-Weighted Signal Intensity of Acute Stroke · Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
7.Which features strengthen the thrombectomy indication in basilar occlusion?
The 2026 guidance supports thrombectomy within 24 hours for selected basilar artery occlusion with substantial neurologic severity and limited established posterior-circulation injury. The principal strong recommendation includes presenting NIHSS at least 10, baseline modified Rankin Scale 0–1, and posterior-circulation ASPECTS at least 6. These features identify the relevant evidence-supported population. Basilar occlusion establishes urgency, but it does not give every patient, severity level, and injury pattern the same expected benefit.
Apply it
A previously independent patient presents eight hours after onset with NIHSS 18, basilar occlusion, and PC-ASPECTS 8. Explain how severity, timing, baseline function, and limited injury support urgent thrombectomy.
Common pitfall: Do not substitute anterior-circulation imaging scores for PC-ASPECTS. Evidence is less established for NIHSS 6–9, so recognition of the occlusion cannot replace assessment of severity.
AHA/ASA: Top Things to Know—2026 Acute Ischemic Stroke Guideline
8.How does transport planning affect access to reperfusion?
Stroke transport decisions balance access to intravenous treatment against timely access to thrombectomy. Destination selection depends on regional travel times, hospital capabilities, the probability of large-vessel occlusion, and the performance of transfer pathways. Organized systems connect prehospital recognition, hospital notification, imaging, and treatment. A destination policy that works in one geography may perform differently where additional travel or interhospital delays change the time to effective treatment.
Apply it
Compare transport to a nearby thrombolysis-capable hospital with direct transport to a more distant thrombectomy center. Include expected travel, treatment, and transfer intervals rather than considering hospital capability alone.
Common pitfall: Neither the closest hospital nor the most advanced hospital is automatically optimal everywhere. Assess the entire pathway and its actual delays before adopting a universal bypass rule.
AHA/ASA: Top Things to Know—2026 Acute Ischemic Stroke Guideline
9.Why does atrial fibrillation change secondary prevention?
Atrial fibrillation supplies a mechanism for cardiac thrombus formation and embolism, so anticoagulation is generally recommended when no contraindication exists. Antiplatelet therapy is not an equivalent substitute for established atrial-fibrillation-associated stroke prevention. The timing of anticoagulation after an acute event requires attention to infarct and bleeding characteristics. Long-term prescribing also requires checking whether a separate indication truly warrants an antiplatelet agent, because combination treatment adds bleeding exposure.
Apply it
A patient with cortical infarction has atrial fibrillation documented during monitoring. Explain why this finding changes the long-term antithrombotic strategy after assessment of acute treatment safety.
Common pitfall: Do not maintain antiplatelet-only treatment merely because it preceded the rhythm diagnosis. Routine addition of antiplatelet therapy to anticoagulation is generally inappropriate without another indication.
AHA/ASA: Top Things to Know—2021 Secondary Stroke Prevention Guideline
10.Who qualifies for short-term aspirin–clopidogrel treatment?
The 2026 standard pathway recommends aspirin plus clopidogrel for eligible noncardioembolic minor ischemic stroke with NIHSS at most 3 or high-risk TIA with ABCD2 at least 4, without intravenous thrombolysis. Initiate within 24 hours of symptom onset and continue for 21 days, then use single antiplatelet therapy. A separate indication supports adding clopidogrel to aspirin for up to 90 days after a recent stroke or TIA attributable to severe, 70–99%, intracranial stenosis. The broader 21–90-day range in the 2021 prevention guideline should not imply routine 90-day treatment for uncomplicated minor stroke or high-risk TIA.
Apply it
For an eligible patient with NIHSS 2 presenting 14 hours after noncardioembolic stroke without thrombolysis, start aspirin–clopidogrel and document transition to monotherapy after 21 days. Consider the separate course of up to 90 days only when severe symptomatic intracranial stenosis establishes that indication.
Common pitfall: Do not replace anticoagulation for atrial fibrillation with dual antiplatelets. These pathways do not authorize immediate antiplatelet treatment after thrombolysis. Continuing aspirin–clopidogrel beyond 90 days increases hemorrhagic risk.
prabhakaran-et-al-2026-2026-guideline-for-the-early-management-of-patients-with-acute-ischemic-stroke-a-guideline-from_%281%29_2.pdf · 56a24fa26d75b4e703ee677cc0309498.pdf · AHA/ASA: Top Things to Know—2021 Secondary Stroke Prevention Guideline
11.Which carotid stenosis is clinically symptomatic?
Carotid stenosis is clinically symptomatic when it corresponds to a recent ipsilateral retinal or hemispheric ischemic event. Territory concordance matters alongside stenosis severity. Severe symptomatic disease may justify early endarterectomy in an appropriate patient, whereas an incidental lesion discovered during an unrelated event has a different benefit-risk assessment. Revascularization planning also considers neurologic stability, infarct burden, disability, anatomy, operative risk, and the timing of the qualifying event.
Apply it
Contrast severe left internal carotid stenosis accompanying transient left monocular vision loss with the same lesion discovered during an unrelated right cerebellar infarct.
Common pitfall: Any prior stroke does not make every carotid lesion symptomatic. Recovery of independence also does not erase the significance of a recent territory-concordant event.
European Stroke Organisation Guideline on Endarterectomy and Stenting for Carotid Artery Stenosis · AHA/ASA: Top Things to Know—2021 Secondary Stroke Prevention Guideline
12.Why is intracranial stenting usually not the initial prevention strategy?
Severe symptomatic intracranial atherosclerotic stenosis calls for intensive medical prevention, including risk-factor treatment and appropriately selected short-term dual antiplatelet therapy. The secondary prevention guideline advises against angioplasty and stenting as first-line treatment. An impressive anatomical narrowing does not establish that instrumentation offers the best initial outcome. This preventive decision differs from thrombectomy for an acute occlusion, where removal of an obstructing clot can restore flow to threatened tissue.
Apply it
A stable patient has a recent territorial TIA and severe intracranial stenosis without an acute occlusion. Explain why medical management begins the prevention plan despite the striking angiographic lesion.
Common pitfall: Do not transfer the benefit of emergency thrombectomy to elective first-line intracranial stenting. Similar vessel locations do not make the clinical indications equivalent.
AHA/ASA: Top Things to Know—2021 Secondary Stroke Prevention Guideline
13.Why does an embolic appearance not establish an anticoagulation indication?
An embolic infarct pattern suggests how an artery became occluded without necessarily identifying the source. Cardiac disease, arterial lesions, and other mechanisms can produce embolism but require different preventive strategies. The secondary prevention guideline advises against empiric anticoagulation for embolic stroke of undetermined source. Appropriate rhythm monitoring and vascular assessment seek a treatment-relevant cause rather than assuming that cortical infarcts prove occult atrial fibrillation.
Apply it
A patient has cortical infarcts without documented atrial fibrillation or another anticoagulation indication. Explain why continued etiologic assessment is preferable to prescribing anticoagulation solely from the imaging pattern.
Common pitfall: An undiscovered source is not an established cardiac source. Conversely, one normal brief rhythm recording does not exclude intermittent atrial fibrillation.
AHA/ASA: Top Things to Know—2021 Secondary Stroke Prevention Guideline
14.Which chronic blood-pressure and lipid targets guide secondary prevention?
For most stroke survivors with hypertension, the chronic outpatient blood-pressure goal is below 130/80 mm Hg. The [2026 dyslipidemia guideline](https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia/top-things-to-know) recommends LDL-C below 55 mg/dL for very-high-risk ASCVD and below 70 mg/dL for ASCVD not at very high risk. Very high risk comprises at least two major ASCVD events, or one major event plus at least two high-risk conditions. Major events include ischemic stroke, myocardial infarction, recent acute coronary syndrome, and symptomatic peripheral arterial disease; high-risk conditions include hypertension, diabetes, smoking, and heart failure. Use maximally tolerated statin therapy and add nonstatin treatment when needed to reach the applicable goal. These LDL categories concern established ASCVD and do not assign every stroke survivor the same target.
Apply it
An atherosclerotic stroke survivor with hypertension and diabetes meets the one-major-event-plus-two-high-risk-conditions route to an LDL-C goal below 55 mg/dL. At follow-up with pressure 146/88 and LDL-C 92 despite a maximally tolerated statin, address adherence, intensify antihypertensive treatment, and add appropriate LDL-lowering therapy such as ezetimibe.
Common pitfall: Do not retain below 70 mg/dL as the sole current ASCVD target or assign below 55 mg/dL to every stroke mechanism. Chronic outpatient goals must remain distinct from acute blood-pressure management during reperfusion or hemorrhage.
15.Which patients have the clearest guideline basis for PFO closure?
For patients aged 18–60 with nonlacunar ischemic stroke unexplained despite thorough evaluation and a PFO with high-risk anatomy, the 2021 guideline considers closure plus long-term antiplatelet treatment reasonable compared with antiplatelet treatment alone. Benefit is less well established without high-risk anatomy. Assess competing mechanisms, including atrial fibrillation and arterial disease. A joint discussion among the patient, neurologist, and cardiologist should address causal likelihood, procedural risk, and expected benefit.
Apply it
A 43-year-old has an unexplained cortical infarct, a large shunt, and atrial septal aneurysm after comprehensive evaluation. Explain why closure is reasonable to discuss in this specific setting.
Common pitfall: An incidental PFO does not prove paradoxical embolism. Do not generalize the recommendation to all ages, lacunar infarcts, or strokes with a clear alternative cause.
16.Which symptom combination should raise suspicion for cervical dissection?
Cervical artery dissection involves arterial wall injury that can produce mural hematoma, luminal narrowing, thrombus, and embolic ischemia. Head or neck pain, ischemic symptoms, cranial nerve manifestations, and partial Horner syndrome are important presentations. Major trauma is not required. New focal pain accompanying a plausible vascular syndrome is particularly useful. After extracranial dissection-associated ischemia, antithrombotic selection is individualized to vessel findings, ischemic manifestations, and bleeding risk.
Apply it
A young adult develops unilateral neck pain followed by transient contralateral weakness. Explain why cervical arterial imaging is indicated even without major trauma or external neck abnormalities.
Common pitfall: Anticoagulation is not mandatory for every dissection. Do not extrapolate extracranial prevention decisions to intracranial dissection presenting with subarachnoid hemorrhage.
AHA: Treatment and Outcomes of Cervical Artery Dissection in Adults · ESO Guideline for the Management of Extracranial and Intracranial Artery Dissection
17.What imaging findings directly support arterial dissection?
Mural hematoma, an intimal flap, and a double lumen directly support arterial dissection. Characteristic caliber changes provide additional information but may be less specific when isolated. CTA and MRI/MRA offer complementary assessment of the lumen and vessel wall; catheter angiography may clarify selected cases. Interpretation combines location, morphology, symptoms, and alternative explanations rather than treating every tapered stenosis as etiologically identical.
Apply it
A painful cervical arterial stenosis is tapered on CTA, while a dedicated wall sequence shows crescentic mural hematoma. Explain why the wall finding strengthens the diagnosis beyond narrowing alone.
Common pitfall: Stenosis describes a lumen rather than its cause. Neither atherosclerosis nor dissection should be inferred solely from reduced caliber without attention to wall findings and clinical context.
ESO Guideline for the Management of Extracranial and Intracranial Artery Dissection
18.How should a suspected vascular malformation change an ICH evaluation?
In a patient younger than 70 with spontaneous lobar ICH, obtain acute CT angiography, with consideration of venography, to identify a macrovascular cause or cerebral venous thrombosis. CTA can reveal an abnormal arterial network, aneurysm, or suspicious enlarged vessels; venography evaluates venous obstruction. When noninvasive imaging suggests a macrovascular lesion, catheter digital subtraction angiography should follow promptly. Its temporal resolution demonstrates arteriovenous shunting and defines feeding arteries and venous drainage: an AVM has a parenchymal nidus with early draining veins, whereas a dural arteriovenous fistula shunts through dural arterial connections without a parenchymal nidus. After negative CTA, MRI/MRA can assess alternative causes, including cavernous malformation and hemorrhagic tumor. Susceptibility-sensitive MRI detects blood products around a cavernous malformation, which may be angiographically occult; contrast-enhanced MRI assesses an underlying mass.
Apply it
A 32-year-old has a lobar hemorrhage with enlarged vessels along its margin. Obtain acute CTA and consider accompanying venography. If CTA suggests an AVM or fistula, proceed promptly to catheter angiography to establish the shunt anatomy. If CTA is unrevealing, MRI with susceptibility-sensitive and contrast-enhanced sequences assesses cavernous malformation or tumor. Catheter angiography remains reasonable in this young patient despite negative noninvasive studies when the cause remains unexplained.
Common pitfall: Elevated admission blood pressure does not establish hypertensive arteriopathy as the cause of a young patient's lobar hemorrhage. A developmental venous anomaly consists of converging veins draining into a collector and does not itself establish an arteriovenous shunt. An associated cavernous malformation may explain hemorrhage. A negative angiogram therefore does not exclude every structural vascular cause.
AHA/ASA: 2022 Spontaneous Intracerebral Hemorrhage Clinical Update · ABPN Vascular Neurology Certification Content Specifications
19.How does cerebral venous thrombosis differ from arterial stroke?
Venous thrombosis obstructs drainage, producing venous hypertension, impaired fluid clearance, edema, and sometimes hemorrhagic injury. Headache, seizures, focal deficits, and raised intracranial pressure can occur in varying combinations. Pregnancy, puerperium, and prothrombotic states are important contexts. Symptoms may evolve over days, and lesions can cross arterial territories. The combination of time course, pressure-related symptoms, and nonterritorial injury should redirect attention from arterial inflow to venous outflow.
Apply it
A postpartum patient develops progressive headache, a seizure, and weakness with a hemorrhagic lesion outside a single arterial territory. Explain why this pattern prioritizes venous imaging.
Common pitfall: Hemorrhage does not exclude thrombosis. Venous obstruction can cause hemorrhagic infarction, so an arterial-only diagnostic framework can miss the initiating process.
AHA: Diagnosis and Management of Cerebral Venous Thrombosis Slide Set
20.Which imaging studies establish cerebral venous thrombosis?
CT venography or MR venography evaluates suspected cerebral venous thrombosis. Routine structural imaging may show edema, hemorrhage, or a suspicious sinus, but a normal or nonspecific noncontrast scan does not reliably exclude venous obstruction. The protocol must assess the venous compartment. Normal variants and technical artifacts can resemble absent flow, so an apparent gap requires correlation with source images, other sequences, or another modality when the finding is uncertain.
Apply it
A patient with progressive headache and papilledema has an unrevealing noncontrast CT. Select venous imaging to test the suspected drainage abnormality rather than repeating structural imaging alone.
Common pitfall: An arterial CTA report does not prove adequate venous assessment. Equally, absent signal on one venographic image does not automatically establish thrombus without anatomical and technical correlation.
AHA: Diagnosis and Management of Cerebral Venous Thrombosis Slide Set
21.Why can anticoagulation be appropriate in hemorrhagic venous infarction?
Hemorrhage in cerebral venous thrombosis can result from drainage obstruction rather than a primary bleeding disorder. Anticoagulation treats the underlying thrombosis and limits propagation, so hemorrhagic venous infarction does not automatically prohibit treatment. Assessment still includes the individual bleeding circumstances, intracranial pressure, and clinical course. The causal distinction matters: a primary spontaneous hemorrhage and a thrombotic obstruction causing secondary hemorrhagic injury are different treatment problems.
Apply it
Venography confirms sinus thrombosis with a small hemorrhagic venous infarct. Explain why treating the clot can be appropriate despite visible blood, while documenting individual contraindications and pressure-related complications.
Common pitfall: Do not apply a blanket rule from primary ICH. Conversely, the venous diagnosis does not justify ignoring active bleeding concerns, clinical deterioration, or a need for surgical treatment.
AHA: Diagnosis and Management of Cerebral Venous Thrombosis Slide Set
22.When does deteriorating venous thrombosis require rescue treatment?
Deterioration during cerebral venous thrombosis may reflect thrombus progression, severe edema, or impending herniation. The rescue intervention should address the dominant mechanism. Endovascular treatment is a selected consideration in patients worsening despite medical treatment, rather than a routine replacement for anticoagulation. Decompressive surgery treats life-threatening mass effect; it does not serve the same immediate purpose as venous recanalization. Reassessment must therefore connect the examination change with repeat vascular and structural findings.
Apply it
A patient develops falling consciousness and increasing hemispheric shift despite anticoagulation. Distinguish treatment of established mass effect from treatment of persistent or progressive venous thrombosis.
Common pitfall: An available endovascular technique is not automatically the correct rescue treatment. Severe herniation risk cannot be assumed to resolve quickly enough through recanalization alone.
AHA: Diagnosis and Management of Cerebral Venous Thrombosis Slide Set
23.How does hemorrhage location inform the etiologic differential?
Deep basal ganglia or thalamic hemorrhage raises concern for perforating-vessel disease associated with hypertension. Lobar hemorrhage broadens consideration of cerebral amyloid angiopathy and structural causes. Location modifies probability rather than establishing a diagnosis. Age, prior vascular risk, antithrombotic exposure, MRI markers, and vascular imaging refine the assessment. An atypical distribution should trigger reconsideration of the presumed cause rather than attribution based only on a high admission blood pressure.
Apply it
Compare deep thalamic hemorrhage in longstanding hypertension with lobar hemorrhage accompanied by superficial siderosis. Describe how the distributions change the differential and the supporting imaging needed.
Common pitfall: Blood pressure can rise after acute hemorrhage. Its elevation does not independently establish chronic hypertensive arteriopathy as the cause of every bleed.
AHA/ASA: 2022 Spontaneous Intracerebral Hemorrhage Clinical Update · The Boston Criteria Version 2.0 for Cerebral Amyloid Angiopathy
24.Which findings support probable cerebral amyloid angiopathy?
CAA involves amyloid-beta deposition in cortical and leptomeningeal vessel walls. Boston criteria version 2.0 permit probable CAA in an eligible patient aged at least 50 with a compatible presentation and either two or more strictly lobar hemorrhagic lesions or one lobar hemorrhagic lesion plus a qualifying white-matter marker. Qualifying markers include severe centrum semiovale perivascular spaces or a multispot white-matter hyperintensity pattern. Deep hemorrhagic lesions and another explanatory cause must be absent.
Apply it
A 74-year-old with spontaneous lobar ICH has strictly lobar microbleeds and cortical superficial siderosis without deep hemorrhagic lesions. Explain how the hemorrhagic route supports probable CAA.
Common pitfall: Do not count deep microbleeds as qualifying lobar lesions. Probable CAA is a clinical-MRI category rather than histologic proof, and age alone is insufficient.
The Boston Criteria Version 2.0 for Cerebral Amyloid Angiopathy · Werring_Boston%20criteria%20R2_4.21.22_AC_CLEAN.pdf
25.What blood-pressure range is recommended for selected acute ICH?
For mild-to-moderate spontaneous ICH presenting with systolic pressure 150–220 mm Hg, lowering toward 140 and maintaining 130–150 mm Hg is safe and may improve functional outcome. Lowering below 130 mm Hg can be harmful. Treatment should provide smooth, sustained control with limited variability. The safety and efficacy of intensive lowering are less established in large or severe hemorrhage and in patients requiring surgical decompression.
Apply it
A patient with mild-to-moderate ICH presents at 186 mm Hg systolic. Use monitored, titratable treatment toward 140 while maintaining the recommended range rather than pursuing the lowest achievable pressure.
Common pitfall: Do not generalize this severity group and presenting-pressure range to every hemorrhage. Chronic outpatient blood-pressure targets also do not replace acute ICH recommendations.
AHA/ASA: 2022 Spontaneous Intracerebral Hemorrhage Clinical Update
26.Which reversal treatments match common antithrombotic exposures in ICH?
Promptly stop the anticoagulant and reverse clinically relevant exposure. For warfarin-associated spontaneous ICH with INR ≥2.0, four-factor PCC is recommended over fresh-frozen plasma for rapid factor replacement. Intravenous vitamin K should follow factor replacement to sustain reversal and prevent INR rebound. With INR 1.3–1.9, PCC may be reasonable; it is not a mandatory recommendation. Idarucizumab specifically reverses dabigatran. For factor Xa inhibitors, establish the agent, last dose, and renal function; a rapidly available drug-calibrated anti-Xa assay can clarify residual activity, but routine PT/INR or aPTT cannot reliably exclude it. Four-factor PCC or activated PCC may be considered for factor Xa inhibitor-associated ICH under the 2022 guideline's Class 2b recommendation. These prohemostatic options carry thrombotic risk, and their clinical-outcome evidence is limited. The historical 2022 recommendation for andexanet alfa must be reconciled with the FDA's subsequent conclusion that Andexxa's serious risks, including thromboembolic events, outweigh its benefits. AstraZeneca ended U.S. commercial sales and manufacture for the U.S. after December 22, 2025. Routine platelet transfusion for aspirin-associated spontaneous ICH without emergency neurosurgery is potentially harmful.
Apply it
Match warfarin with INR 3.4 to prompt four-factor PCC followed immediately by intravenous vitamin K. PCC replaces depleted coagulation factors rapidly, while vitamin K supports renewed synthesis of functional factors. For ICH three hours after apixaban, promptly assess meaningful exposure and consider four-factor PCC or activated PCC under the institutional emergency reversal protocol; a normal routine coagulation result does not establish absence of anticoagulant activity.
Common pitfall: Do not extend the strong PCC recommendation for warfarin-associated ICH with INR ≥2.0 to every mildly elevated INR. Vitamin K and idarucizumab do not reverse apixaban. PCC supplies coagulation factors rather than removing the factor Xa inhibitor. Do not present historical andexanet recommendations as current U.S. availability or portray PCC benefit as established by definitive outcome trials.
AHA/ASA: 2022 Spontaneous Intracerebral Hemorrhage Clinical Update · Update on the Safety of Andexxa by AstraZeneca: FDA Safety Communication | FDA
27.When is ventricular drainage indicated after hemorrhage?
Intraventricular blood can obstruct cerebrospinal fluid circulation, causing hydrocephalus and reduced consciousness. When hydrocephalus contributes to impaired consciousness after intracerebral or intraventricular hemorrhage, ventricular drainage targets a reversible pressure-related mechanism. This differs from evacuation of the parenchymal hematoma. The indication depends on the clinical effect of obstruction and supporting imaging, rather than the mere presence of ventricular blood in an otherwise stable patient.
Apply it
A patient with thalamic hemorrhage becomes less responsive while CT shows enlarging ventricles. Explain why drainage assessment addresses a new complication even if the original hematoma remains unchanged.
Common pitfall: Do not attribute every decline to irreversible tissue destruction. Conversely, ventricular blood alone does not establish that symptomatic hydrocephalus is present or that drainage is indicated.
AHA/ASA: 2022 Spontaneous Intracerebral Hemorrhage Clinical Update
28.When does cerebellar ICH require immediate surgical removal?
Immediate surgical removal of cerebellar ICH, with ventricular drainage when appropriate, is recommended to reduce mortality when there is neurologic deterioration, brainstem compression, obstructive hydrocephalus, or hematoma volume at least 15 mL. The volume threshold is an independent indication; deterioration need not occur first. Posterior-fossa confinement makes compression and fourth-ventricle obstruction dangerous. Ventricular drainage can address hydrocephalus but does not remove a compressive cerebellar mass.
Apply it
An alert patient has an 18-mL cerebellar hemorrhage. Explain why the volume already supports surgery; then contrast a smaller hemorrhage that qualifies through deterioration or brainstem compression.
Common pitfall: Do not wait for clinical decline when an independent indication is present. Distinguish relief of CSF obstruction from removal of the posterior-fossa hematoma.
AHA/ASA: 2022 Spontaneous Intracerebral Hemorrhage Clinical Update
29.Why must swallowing safety be assessed before oral intake?
Stroke can impair swallowing through cortical, subcortical, or brainstem injury, creating aspiration risk that cannot be reliably inferred from limb strength or conversational ability. The ICH guideline supports formal dysphagia screening before oral intake. A failed screen requires further assessment and an appropriate nutrition and medication route. Swallowing safety applies to water and tablets as well as meals; an oral prescription still creates an exposure that requires safe swallowing.
Apply it
A patient speaks clearly and requests water with medication before screening. Explain why preserved speech does not establish safe swallowing and arrange the screening pathway before oral administration.
Common pitfall: A reassuring motor examination is not a swallowing test. Avoid informal trial intake that bypasses screening, and ensure alternative medication and nutrition plans follow the assessment.
AHA/ASA: 2022 Spontaneous Intracerebral Hemorrhage Clinical Update
30.Why is securing a ruptured aneurysm a distinct treatment objective?
After aneurysmal SAH, the ruptured aneurysm remains a source of rebleeding until appropriately treated. Early aneurysm treatment, with complete obliteration when feasible, addresses that source. Coiling and clipping require assessment of anatomy and patient factors by clinicians with relevant expertise. This objective differs from prevention of delayed cerebral ischemia, treatment of hydrocephalus, and management of systemic complications. Success in one component does not eliminate the remaining hazards.
Apply it
A stable patient improves after initial resuscitation. Explain why improvement does not remove the need for prompt aneurysm treatment and why nimodipine serves a separate purpose.
Common pitfall: Nimodipine does not secure an aneurysm. Conversely, successful aneurysm occlusion does not eliminate delayed ischemia or other complications requiring continued monitoring and treatment.
AHA/ASA: Top Things to Know—2023 Aneurysmal Subarachnoid Hemorrhage Guideline
31.What benefit does nimodipine provide after aneurysmal hemorrhage?
Early enteral nimodipine after aneurysmal SAH helps prevent delayed cerebral ischemia and improves functional outcomes. Its value should not be reduced to whether a single angiogram shows less arterial narrowing. Angiographic vasospasm and the clinical syndrome of delayed ischemia are related but distinct. Nimodipine complements aneurysm treatment and attentive critical care; it does not replace investigation when a patient develops new weakness, language impairment, or reduced consciousness.
Apply it
A patient receiving nimodipine develops a new deficit several days after SAH. Explain why preventive treatment does not exclude delayed ischemia and identify the competing complications requiring assessment.
Common pitfall: Do not describe nimodipine as aneurysm occlusion or anticoagulant reversal. Prevention reduces risk rather than guaranteeing that the targeted complication cannot occur.
AHA/ASA: Top Things to Know—2023 Aneurysmal Subarachnoid Hemorrhage Guideline
32.How is delayed cerebral ischemia distinguished from other causes of decline?
New neurologic deterioration after aneurysmal SAH requires assessment for delayed cerebral ischemia and alternatives including rebleeding, hydrocephalus, seizures, and systemic disturbances. Timing and examination raise suspicion, but arterial narrowing alone does not establish the cause of decline. Diagnosis connects the clinical change to vascular and tissue findings while evaluating competing explanations. This matters because treatment of ventricular obstruction, an electrographic seizure, and symptomatic ischemia addresses different mechanisms.
Apply it
A previously improving patient develops aphasia several days after aneurysm treatment. CT excludes new hemorrhage and ventricular enlargement; use those findings to narrow rather than prematurely close the differential.
Common pitfall: Do not label every delayed decline vasospasm. A compelling temporal pattern still requires consideration of structural, electrical, metabolic, and medication-related explanations.
AHA/ASA: Top Things to Know—2023 Aneurysmal Subarachnoid Hemorrhage Guideline
33.Why is euvolemia preferred to prophylactic hypervolemia after SAH?
Volume management after aneurysmal SAH aims to maintain adequate circulating volume while avoiding unnecessary fluid excess. The guideline favors euvolemia and discourages prophylactic hypervolemia. Avoiding depletion supports cerebral perfusion, but administering fluid beyond physiologic need is not automatically protective. Blood-pressure elevation may help selected patients with symptomatic delayed cerebral ischemia. That targeted treatment is different from routine hemodynamic augmentation in every patient before symptoms develop.
Apply it
A stable patient receives extra fluid solely to prevent future vasospasm despite no evidence of depletion. Explain why the appropriate goal is euvolemia rather than preventive fluid overload.
Common pitfall: Do not bundle historical hemodynamic strategies into routine care. Prevention in a stable patient and treatment of established symptomatic ischemia have different indications and risks.
AHA/ASA: Top Things to Know—2023 Aneurysmal Subarachnoid Hemorrhage Guideline
34.Why does aneurysm surveillance continue after initial treatment?
Initial aneurysm treatment does not guarantee absence of residual, recurrent, or additional vascular lesions. Follow-up cerebrovascular imaging can detect residual filling, recurrence, changes in another known aneurysm, or a newly developed aneurysm. Surveillance planning should identify the treatment performed, completeness of occlusion, other lesions, and the team responsible for reviewing results. A follow-up study provides benefit only when findings are interpreted and incorporated into subsequent care.
Apply it
A patient wants to skip surveillance because the ruptured aneurysm was treated. Explain the different abnormalities follow-up can identify and assign responsibility for reviewing the planned study.
Common pitfall: Successful acute treatment does not establish lifetime absence of aneurysm risk. Conversely, an abnormal surveillance image does not mean that every lesion requires immediate intervention.
AHA/ASA: Top Things to Know—2023 Aneurysmal Subarachnoid Hemorrhage Guideline
35.Which findings localize ischemia to the lateral medulla?
Lateral medullary infarction can combine vestibular symptoms, ataxia, crossed sensory findings, Horner syndrome, and bulbar dysfunction. Ipsilateral facial and contralateral body sensory abnormalities indicate involvement of different pathways within the brainstem. Dysphagia and dysphonia signal bulbar involvement and immediate functional risk. Lesion level and extent influence the pattern, so no single feature is obligatory. The complete constellation provides more reliable localization than vertigo or sensory loss considered alone.
Apply it
Vertigo, ipsilateral facial pain-temperature loss, contralateral body loss, and hoarseness support lateral medullary localization. Explain the associated swallowing concern even without dense limb weakness.
Common pitfall: Absence of major weakness does not make a brainstem stroke minor or peripheral. A peripheral vestibular disorder cannot explain the crossed sensory and bulbar findings together.
36.How does PRES differ from a territorial arterial infarct?
PRES commonly presents with seizures, encephalopathy, headache, or visual disturbance in settings such as severe hypertension, renal disease, eclampsia, or certain drug exposures. Imaging often shows posterior-predominant vasogenic edema rather than a single arterial-territory infarct. Abnormalities may extend beyond posterior regions, and recovery is not guaranteed. The discriminating combination is the systemic setting, clinical syndrome, edema characteristics, and distribution rather than the word posterior alone.
Apply it
A hypertensive patient with renal disease develops confusion, seizures, and bilateral posterior edema. Explain why this combination favors PRES over a single posterior cerebral artery infarct.
Common pitfall: Reversible does not mean harmless. Atypical distribution, restricted diffusion, or permanent injury can occur, so neither posterior confinement nor complete recovery is obligatory.
Posterior Reversible Encephalopathy Syndrome: Associated Clinical and Radiologic Findings
37.What pattern distinguishes reversible cerebral vasoconstriction syndrome?
RCVS characteristically produces recurrent thunderclap headaches with multifocal arterial narrowing that resolves over time. Vasoactive exposures and postpartum states are important associations. Ischemic stroke and convexity subarachnoid hemorrhage can complicate the syndrome. Recurring abrupt headaches and subsequent vascular reversibility supply useful temporal evidence; narrowing alone is nonspecific. The diagnosis therefore depends on longitudinal clinical and imaging information rather than an isolated beaded angiogram.
Apply it
A patient taking a vasoactive substance experiences repeated maximal-intensity headaches over a week. Explain how follow-up resolution of multifocal narrowing strengthens the diagnosis and separates it from persistent arteriopathy.
Common pitfall: Do not assume thunderclap headache is benign or that beading proves inflammatory vasculitis. Suspected RCVS still requires assessment for hemorrhage, ischemia, and alternative causes.
38.When should recurrent small-vessel stroke suggest CADASIL?
CADASIL is an inherited cerebral small-vessel disorder associated with pathogenic NOTCH3 variants. Recurrent subcortical ischemic events, migraine, and cognitive impairment across generations can suggest a Mendelian process rather than sporadic vascular disease alone. Family history and phenotype help identify when targeted genetic assessment is appropriate. A common family history of late-life stroke is much less specific than similar early neurologic disease recurring across generations.
Apply it
A relatively young patient has recurrent subcortical strokes, migraine, and a parent with early stroke and dementia. Explain why the combined phenotype warrants consideration of NOTCH3-related disease.
Common pitfall: Not every NOTCH3 finding is pathogenic, and not every familial stroke syndrome is CADASIL. Molecular classification must be interpreted alongside the patient's phenotype and inheritance pattern.
Notch3 Mutations in CADASIL, a Hereditary Adult-Onset Condition Causing Stroke and Dementia
39.How should rehabilitation timing and intensity be selected after ICH?
For selected patients with moderate ICH, stretching and functional task training may begin 24–48 hours after onset. Very early intensive mobilization within the first 24 hours can be harmful. Timing and intensity are separate variables: supervised activity after stabilization differs from aggressive mobilization during evolving hemorrhage. Coordinate physical, occupational, speech, swallowing, and nutritional assessment with neurologic and hemodynamic stability and the patient's specific functional deficits.
Apply it
Compare supervised task practice at 30 hours in a stable patient with intensive out-of-bed activity at eight hours during fluctuating symptoms and unstable pressure.
Common pitfall: Early rehabilitation does not mean maximum activity immediately. The 24–48-hour option requires patient selection and cannot override instability, swallowing risk, or activity-specific precautions.
AHA/ASA: 2022 Spontaneous Intracerebral Hemorrhage Clinical Update
55.How does sickle-cell disease change secondary stroke prevention?
Sickle-cell disease can cause cerebral arteriopathy, thrombosis, and hypoperfusion. After ischemic stroke or TIA, chronic transfusion to reduce hemoglobin S below 30% is recommended to prevent recurrence. When transfusion is unavailable or impractical, hydroxyurea is a reasonable alternative. This disease-specific strategy requires hematology coordination and monitoring rather than assuming that ordinary antiplatelet prescribing fully addresses the mechanism. Evaluation should still consider an additional coexisting cause of stroke.
Apply it
A young person with sickle-cell disease has a prior ischemic stroke. Coordinate chronic transfusion planning and hemoglobin S monitoring alongside the broader neurologic prevention plan.
Common pitfall: The recommendation concerns secondary prevention. Do not treat hydroxyurea as automatically equivalent to feasible transfusion or allow the sickle-cell diagnosis to obscure another established stroke mechanism.
Neuroinfectious diseases1–2%
43.How should suspected infection be evaluated after ventricular drainage?
An external ventricular drain can introduce organisms into the cerebrospinal fluid. New fever, worsening consciousness, and increasing CSF leukocytes raise concern for ventriculitis or meningitis, but hemorrhage itself can alter CSF cell counts, glucose, and protein. CSF cultures help establish an infectious explanation, while structural imaging assesses competing causes such as hydrocephalus or new bleeding. Interpret laboratory changes alongside symptoms, device exposure, prior treatment, and the evolving clinical course.
Apply it
After ICH and drainage, a patient develops fever and reduced alertness without new hemorrhage. Investigate infection with appropriate CSF studies while checking device function and other causes of decline.
Common pitfall: Bloody CSF does not exclude infection, and an isolated abnormal cell count does not establish it. Avoid interpreting a possible contaminant independently of symptoms and repeated findings.
ABPN Vascular Neurology Certification Content Specifications · IDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis
Brain and spinal trauma and spinal diseases1–2%
44.How does acute spinal cord ischemia differ from compressive myelopathy?
Rapid bilateral weakness, a sensory level, and sphincter dysfunction localize to the spinal cord rather than a single cerebral hemisphere. Spinal infarction, epidural hematoma, and other compressive lesions require different treatment paths. Urgent spine MRI evaluates compression and cord injury; diffusion findings can support ischemia, while an epidural compressive lesion identifies a mechanical threat. Early imaging can be nondiagnostic, and T2 hyperintensity alone does not establish an inflammatory cause. The [original spinal infarction study by Zalewski and colleagues](https://jamanetwork.com/journals/jamaneurology/fullarticle/2702589) supports exclusion of compression, DWI/ADC restriction as a specific imaging finding, and repeat imaging when an initially normal MRI leaves ischemia suspected.
Apply it
A patient develops paraplegia, a thoracic sensory level, and retention over two hours. Obtain spine imaging to distinguish infarction from an epidural lesion before labeling the syndrome transverse myelitis. If the initial study excludes compression but remains nondiagnostic, maintain the ischemic differential and arrange repeat MRI.
Common pitfall: Do not infer etiology from localization alone. A normal early study or nonspecific cord signal cannot independently exclude ischemia or prove inflammation.
ABPN Vascular Neurology Certification Content Specifications
Neuro-ophthalmologic and neuro-otologic disorders1–2%
45.When does a painful partial Horner syndrome suggest carotid disease?
Cervical internal carotid dissection can disrupt adjacent sympathetic pathways and produce partial Horner syndrome, typically ptosis and miosis. New ipsilateral head or neck pain makes this ocular pattern an important arterial clue, even before a hemispheric infarct develops. The diagnostic value comes from the combination of local pain and sympathetic findings. Preserved visual acuity or limb strength does not exclude an arterial wall injury.
Apply it
A patient develops unilateral neck pain, subtle eyelid droop, and a smaller pupil on the same side. Explain why cervical vascular assessment is warranted despite normal strength and vision.
Common pitfall: Do not require a complete classic triad or completed stroke before considering dissection. Pupil asymmetry alone is nonspecific and must be interpreted with the accompanying findings.
AHA: Treatment and Outcomes of Cervical Artery Dissection in Adults
Metabolic diseases, nutritional deficiency states, and disorders due to toxins, drugs, and physical agents1–2%
46.Why can intensive glucose lowering cause harm during acute ischemic stroke?
Acute glucose management balances hyperglycemia against treatment-induced hypoglycemia. The 2026 guidance does not recommend intensive control to 80–130 mg/dL to improve ischemic stroke outcomes because severe hypoglycemia increases without the intended clinical benefit. Improving a laboratory value more aggressively is therefore not equivalent to improving brain recovery. Nutrition, monitoring, and changing insulin requirements matter when selecting and adjusting inpatient treatment.
Apply it
A service proposes targeting 90 mg/dL in every hyperglycemic stroke patient. Explain why that intensive target is not an outcome-improving stroke intervention and requires revision.
Common pitfall: Do not import chronic outpatient glycemic goals into acute neurologic care. A lower measured glucose is not proof of a better functional outcome, particularly when achieved through hypoglycemic episodes.
AHA/ASA: Top Things to Know—2026 Acute Ischemic Stroke Guideline
Behavioral neurology and neurocognitive disorders1–2%
47.How does neglect differ from weakness or visual-field loss?
Spatial neglect is impaired attention or response to one side of space that is not fully explained by primary sensory or motor loss. It commonly accompanies right hemispheric injury with left-sided inattention. Assess fields and strength separately. The [European Academy of Neurology recommendations for neglect screening](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544365/) favor a standardized cancellation task when only one rapid screen is feasible; figure copying and line bisection can provide additional information. Assess extinction during bilateral stimulation and observe everyday spatial behavior. Formal diagnosis requires multiple complementary assessments because a single task can miss clinically important neglect.
Apply it
A patient detects isolated left stimuli but misses them during simultaneous bilateral presentation and ignores the left side of a drawing. Document attention separately from hemianopia and weakness, add a standardized cancellation task, and assess the effect on grooming or navigation.
Common pitfall: Do not diagnose neglect from a field cut alone. Preserved strength or single-stimulus detection does not exclude disabling inattention. A normal NIHSS attention item or isolated line-bisection result is insufficient to establish intact spatial attention.
ABPN Vascular Neurology Certification Content Specifications
Questions not associated with a specific neurologic disorder7–11%
49.How is absolute risk reduction calculated?
Absolute risk reduction is the control event risk minus the treatment event risk for the same outcome and follow-up period. A reduction from 12% to 8% equals four percentage points, or 0.04. This describes the incremental benefit rather than either group's event risk alone. Absolute effects support clinical decisions because identical relative effects can yield very different numbers of prevented events at different baseline risks.
Apply it
A two-year trial reports recurrent stroke in 15% of controls and 10% of treated participants. Report five fewer events per 100 treated over two years.
Common pitfall: Do not confuse percentage points with percentage change or combine different follow-up intervals. The outcome definition and comparison must match before subtracting risks.
Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
50.How should number needed to treat be interpreted?
Number needed to treat for an additional beneficial outcome is the reciprocal of absolute risk reduction expressed as a proportion. An absolute reduction of 0.04 gives an NNT of 25. Interpretation names the outcome, comparison, population, and follow-up period; NNT is not a permanent property of a drug. When a whole-person result is needed, round a noninteger upward. Uncertainty in the treatment effect should remain part of interpretation.
Apply it
A three-year trial reduces risk from 11% to 7.5%. Calculate 1 divided by 0.035 and report an NNT of 29 over three years.
Common pitfall: Entering 3.5 instead of 0.035 produces a unit error. Rounding downward exaggerates benefit, and omitting the follow-up period leaves the estimate clinically incomplete.
Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
51.Why must the measured outcome be checked before applying a trial result?
A treatment effect answers the outcome actually measured. Improvement in an imaging marker, composite endpoint, or disability scale cannot automatically establish a specific mortality benefit. Examine the contributing events, measurement method, follow-up period, and relevance to the patient. A statistically favorable summary may be clinically useful while still supporting a narrower conclusion than a general claim that treatment improves every important outcome.
Apply it
A report shows fewer composite vascular events. Before describing a survival advantage, inspect mortality results and determine which components account for the observed difference.
Common pitfall: Do not assume every component improves equally. A composite driven by frequent less-severe events has a different interpretation from a demonstrated reduction in death or disabling stroke.
Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
52.How does baseline risk alter expected absolute benefit?
Absolute benefit depends on baseline risk as well as relative treatment effect. Assuming a constant relative risk reduction, higher-risk populations experience larger absolute reductions. Applying a trial therefore requires comparing the patient's untreated risk with the study population and checking whether the relative effect is plausibly transferable. This calculation makes assumptions explicit rather than treating a published NNT as equally applicable to every patient.
Apply it
A 20% relative reduction applied to baseline risks of 20% and 5% gives absolute reductions of four and one percentage points over the same interval.
Common pitfall: Do not carry a trial's NNT unchanged into every risk group. Constant relative benefit is itself an assumption, and differences in population or competing events can affect applicability.
Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
Neuroimmunologic and paraneoplastic CNS disorders1–2%
48.What distinguishes suspected CNS angiitis from reversible vasoconstriction?
Primary CNS angiitis is an inflammatory vessel disorder that can produce headache, cognitive change, seizures, and multifocal ischemia. Infarcts of different ages, inflammatory CSF, and persistent vascular abnormalities support investigation but remain nonspecific. RCVS more characteristically combines recurrent thunderclap headache with narrowing that reverses over time. Infectious and systemic causes must also be evaluated. Angiography describes luminal disease; targeted brain or leptomeningeal biopsy can provide tissue evidence and identify alternatives.
Apply it
Progressive cognitive symptoms, recurrent infarcts, CSF pleocytosis, and persistent narrowing favor investigation for inflammation or infection over assuming uncomplicated RCVS.
Common pitfall: Beading and vessel-wall enhancement do not independently prove vasculitis. Do not commit to prolonged immunosuppression solely from nonspecific imaging without evaluating infectious and other mimics.
ABPN Vascular Neurology Certification Content Specifications · The Clinical and Radiological Spectrum of Reversible Cerebral Vasoconstriction Syndrome: A Prospective Series of 67 Patients · 56a24fa26d75b4e703ee677cc0309498.pdf
Neuroscience and mechanism of disease8–12%
53.Why do collateral vessels influence the pace of ischemic injury?
Collateral circulation can preserve some downstream perfusion despite an arterial occlusion, slowing progression from threatened tissue to irreversible injury. This helps explain different core estimates in patients with similar occlusion sites and elapsed times. Collateral support is incomplete and may fail, so favorable physiology still demands urgency. Perfusion-selected thrombectomy research demonstrates the clinical importance of identifying retained salvageable tissue rather than assuming that elapsed time completely determines tissue state.
Apply it
Two patients arrive eight hours after comparable proximal occlusions, but their estimated cores differ markedly. Explain how residual collateral flow can account for the discrepancy.
Common pitfall: A small late core does not make waiting safe. Imaging describes current physiology, and persistent occlusion can still lead to rapid deterioration if collateral support falls.
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
Clinical aspects of neurologic disease22–28%
54.How should a new neurologic deficit after stroke change the differential?
New deterioration during stroke hospitalization can reflect recurrent ischemia, hemorrhagic transformation, expanding edema, hydrocephalus, seizure, or a systemic complication. The original disease, timing, examination, and new findings determine the differential. Avoid anchoring on the admission diagnosis. Treatable complications such as ventricular obstruction and electrographic seizures require different tests and interventions, so identifying the mechanism matters more than simply documenting that the patient is worse.
Apply it
For fluctuating responsiveness after ICH, compare repeat structural imaging for hemorrhage or hydrocephalus with EEG for a nonconvulsive electrical explanation.
Common pitfall: A stable admission scan does not exclude a later complication. Conversely, one negative test cannot exclude mechanisms that it was not designed to assess.
AHA/ASA: 2022 Spontaneous Intracerebral Hemorrhage Clinical Update
Diagnostic procedures22–28%
3.Which questions do structural, vascular, and perfusion imaging answer?
Acute stroke imaging answers complementary questions. Noncontrast CT assesses hemorrhage and visible tissue injury. Vascular imaging identifies arterial occlusion or another vascular lesion. Perfusion imaging estimates hemodynamic disturbance and the relationship between severely injured and threatened tissue. A normal early noncontrast CT does not establish normal arterial flow. Imaging selection should therefore follow the clinical decision: excluding hemorrhage, identifying a treatment target, and assessing tissue viability are related but separate objectives.
Apply it
A patient has abrupt aphasia and hemiparesis without hemorrhage on CT. Select arterial imaging to identify a proximal occlusion rather than treating the structural scan as a vascular examination.
Common pitfall: Do not regard the modalities as interchangeable. Additional testing should answer a relevant selection question without creating avoidable delay in an otherwise eligible treatment pathway.
ABPN Vascular Neurology Certification Content Specifications · Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
Treatment/Management31–39%
56.How do timing and age influence carotid revascularization choice?
For appropriate patients with severe symptomatic carotid stenosis, endarterectomy is generally recommended early, ideally within two weeks of the last retinal or cerebral ischemic event. Neurologic status, anatomy, comorbidity, and procedural risk affect selection. Age also matters: the ESO guideline generally favors endarterectomy over stenting in older patients, while stenting may be considered in selected younger patients. An apparently less invasive procedure does not automatically have the lowest stroke risk.
Apply it
A stable 77-year-old with a recent nondisabling ipsilateral event and acceptable surgical risk should receive early endarterectomy assessment rather than automatic delayed stenting.
Common pitfall: Do not postpone every symptomatic lesion for months. Large disabling infarction, unstable illness, and prohibitive procedural risk require a different individualized benefit-risk assessment.
European Stroke Organisation Guideline on Endarterectomy and Stenting for Carotid Artery Stenosis
Interpersonal and communication skills1–2%
57.How can treatment benefit be explained without overstating certainty?
A treatment conversation should state the outcome, comparison, absolute difference, and follow-up period in understandable language. Relate benefits and harms to the patient's priorities and check understanding. Relative reductions alone can sound more impressive than their corresponding absolute differences. A group average also does not guarantee an individual's result. Accurate patient and family education connects numerical evidence with the decision the patient actually faces.
Apply it
Translate a one-third relative reduction from 9% to 6% over two years into three fewer events per 100 treated, then discuss burdens and uncertainties.
Common pitfall: Do not select only the most persuasive number. Avoid assuming silence means understanding, and distinguish a patient's informed preference from agreement produced by unclear framing.
Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions · ABPN Vascular Neurology Certification Content Specifications
Professionalism1–2%
58.Why should an ICH severity score not dictate withdrawal of treatment?
An ICH severity score summarizes illness and can support communication, but it should not be the sole basis for individual prognosis or limitation of life-sustaining treatment. Early pessimistic decisions can contribute to self-fulfilling outcomes. Prognosis also depends on evolving complications and treatment response. Ethical discussions include uncertainty, known patient values, and applicable directives. A do-not-attempt-resuscitation decision does not automatically authorize withholding other appropriate medical or surgical care.
Apply it
When a family hears that an admission score makes recovery impossible, separate population-level risk from individual certainty and explore the patient's previously expressed wishes.
Common pitfall: Do not equate resuscitation preferences with refusal of all care. Avoiding premature certainty also does not justify disregarding an applicable advance directive or established patient preference.
AHA/ASA: 2022 Spontaneous Intracerebral Hemorrhage Clinical Update
Practice-based learning and improvement1–2%
59.How can a stroke service measure whether a workflow change works?
Quality improvement begins with a defined problem, reproducible measure, and intervention linked to a plausible cause. A stroke service might measure treatment delays while monitoring eligibility decisions and complications. Faster processing alone does not prove improved patient outcomes or establish causation. Keep the denominator and case definition consistent, examine performance over time, and assess whether apparent improvement reflects case mix or concurrent changes.
Apply it
After introducing single-call activation, measure treatment times in a defined eligible population and add a balancing measure for incomplete safety assessment or treatment complications.
Common pitfall: Do not select only favorable cases or alter the denominator after implementation. A before-and-after difference is a useful signal but is not automatically proof that the intervention caused it.
ABPN Vascular Neurology Certification Content Specifications · AHA/ASA: Top Things to Know—2026 Acute Ischemic Stroke Guideline
Systems-based practice1–3%
60.What information makes an interhospital stroke transfer actionable?
A reperfusion transfer must preserve last known well, symptom discovery, current disabling deficits, baseline function, treatments actually administered, relevant contraindications, and accessible imaging. These facts allow the receiving team to prepare without reconstructing essential history after arrival. Order times and administration times should remain distinct, as should current disability and premorbid function. Coordinated information transfer is part of timely access to the appropriate treatment level.
Apply it
Before transferring a patient with proximal occlusion, send source images, timing history, examination findings, baseline function, and actual thrombolytic administration details to the receiving team.
Common pitfall: A statement that the patient has a stroke is insufficient. Rapid physical transport can still lose valuable clinical time when decision-critical images or treatment details are missing.
AHA/ASA: Top Things to Know—2026 Acute Ischemic Stroke Guideline · ABPN Vascular Neurology Certification Content Specifications
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Connect vascular mechanisms with localization, imaging selection, acute treatment, secondary prevention, and rehabilitation.
- Distinguish disabling from nondisabling deficits and separate thrombolysis selection, thrombectomy selection, and historical trial enrollment criteria.
- Compare arterial occlusion, venous thrombosis, hemorrhage, RCVS, PRES, dissection, and inflammatory arteriopathy through time course and imaging distribution.
- Recognize reversible complications including hydrocephalus, seizures, delayed cerebral ischemia, aspiration risk, infection, and posterior-fossa compression.
- Study migraine aura, sleep apnea, spinal disease, neuro-ophthalmologic clues, metabolic treatment effects, neglect, and neuroimmunologic mimics.
- Practise absolute-effect calculations, informed communication, ethical prognosis, quality improvement, and coordinated transfers.
- Use the official detailed outline to complete topics beyond these selective lessons and to review both classification dimensions.
A practical preparation plan
1. Map the full outline
Use the 11 disorder/topic domains as rows and the eight competency/mechanism domains as columns. Mark studied topics against the detailed official outline. Allocate most time to vascular disease while retaining deliberate review of each smaller domain.
2. Rehearse acute decisions
For each case, state last known well, discovery time, functional disability, hemorrhage status, vascular target, relevant tissue findings, and treatment constraints. Explain which finding changes the intervention.
3. Contrast neighboring diagnoses
Compare aura with TIA, RCVS with CNS angiitis, PRES with arterial infarction, spinal infarction with compression, and primary ICH with hemorrhagic venous infarction. Name the decisive clinical and imaging cues.
4. Link deterioration to targeted tests
Before ordering studies, generate a mechanism-based differential. Explain what repeat CT, arterial imaging, venography, CSF studies, and EEG can establish and which findings require urgent intervention.
5. Use questions to diagnose weaknesses
Complete the 20 questions and explain why each alternative is less appropriate. Classify errors by mechanism, clinical assessment, diagnosis, or management. Revisit the 20 flashcards later without answer options.
6. Integrate professional practice
Practise explaining absolute benefits, discussing uncertain prognosis, preserving patient preferences, improving workflows, and transferring treatment-critical information. Return to the official outline to identify remaining gaps.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABPN: Vascular Neurology
- ABPN Vascular Neurology Certification Content Specifications
- AHA/ASA: Top Things to Know—2026 Acute Ischemic Stroke Guideline
- AHA/ASA: Top Things to Know—2021 Secondary Stroke Prevention Guideline
- AHA: Treatment and Outcomes of Cervical Artery Dissection in Adults
- AHA: Diagnosis and Management of Cerebral Venous Thrombosis Slide Set
- AHA/ASA: 2022 Spontaneous Intracerebral Hemorrhage Clinical Update
- AHA/ASA: Top Things to Know—2023 Aneurysmal Subarachnoid Hemorrhage Guideline
- Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
- Evolution of Apparent Diffusion Coefficient, Diffusion-Weighted, and T2-Weighted Signal Intensity of Acute Stroke
- Notch3 Mutations in CADASIL, a Hereditary Adult-Onset Condition Causing Stroke and Dementia
- International Headache Society: ICHD-3—Migraine with Aura
- AASM Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea
- Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
- ESO Guideline for the Management of Extracranial and Intracranial Artery Dissection
- The Boston Criteria Version 2.0 for Cerebral Amyloid Angiopathy
- Pure Lateral Medullary Infarction: Clinical-Radiological Correlation of 130 Acute, Consecutive Patients
- Posterior Reversible Encephalopathy Syndrome: Associated Clinical and Radiologic Findings
- The Clinical and Radiological Spectrum of Reversible Cerebral Vasoconstriction Syndrome: A Prospective Series of 67 Patients
- European Stroke Organisation Guideline on Endarterectomy and Stenting for Carotid Artery Stenosis
- Vascular-Neurology-Certification-Format-and-Scoring.pdf
- 56a24fa26d75b4e703ee677cc0309498.pdf
- Werring_Boston%20criteria%20R2_4.21.22_AC_CLEAN.pdf
- prabhakaran-et-al-2026-2026-guideline-for-the-early-management-of-patients-with-acute-ischemic-stroke-a-guideline-from_%281%29_2.pdf
- Update on the Safety of Andexxa by AstraZeneca: FDA Safety Communication | FDA
- diagnostic-testing-osa.pdf
- IDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.